Dostarlimab with platinum-based chemotherapy for advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiency [ID6415]

Suggested remit: To appraise the clinical and cost effectiveness of dostarlimab with platinum-based chemotherapy within its marketing authorisation for treating primary advanced or recurrent endometrial cancer with microsatellite stable (MSS) or mismatch repair proficient (pMMR) tumours in adults.

Status:

In progress

Technology type:

Medicine

Decision:

Selected

Reason for decision:

Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources

Process:

STA Standard

ID number:

6415

Provisional Schedule

Draft guidance: 1:

30 July 2025 - 20 August 2025

Expected publication:

10 September 2025

Project Team

Project lead

Jen Upton

Email enquiries

If you have any queries please email [email protected]

External Assessment Group:

BMJ Technology Assessment Group (BMJ-TAG), BMJ

Stakeholders

Companies sponsors

GlaxoSmithKline (dostarlimab)

Others

Department of Health and Social Care

 

NHS England

Patient carer groups

Peaches Womb Cancer Trust

Professional groups

Association of Cancer Physicians

 

Cancer Research UK

 

Royal College of Physicians

 

Royal College of Radiologists

Associated public health groups

None

Comparator companies

AstraZeneca (durvalumab, olaparib) (confidentiality agreement signed, participating)

 

Merck Sharp & Dohme (pembrolizumab) (confidentiality agreement signed, participating)

 

Accord (carboplatin, paclitaxel, cisplatin, doxorubicin) (confidentiality agreement not signed, not participating)

 

Alliance Healthcare (cyclophosphamide, paclitaxel) (confidentiality agreement not signed, not participating)

 

Bausch & Lomb (megestrol acetate) (confidentiality agreement not signed, not participating)

 

Baxter Healthcare (cyclophosphamide) (confidentiality agreement not signed, not participating)

 

Bristol Myers Squibb Pharmaceuticals (paclitaxel) (confidentiality agreement not signed, not participating)

 

Consilient Health (carboplatin) (confidentiality agreement not signed, not participating)

 

Fresenius Kabi (carboplatin, paclitaxel) (confidentiality agreement not signed, not participating)

 

Hospira UK (carboplatin, paclitaxel) (confidentiality agreement not signed, not participating)

 

Johnson & Johnson Innovative Medicine (doxorubicin) (confidentiality agreement not signed, not participating)

 

Medac GmbH (doxorubicin) (confidentiality agreement not signed, not participating)

 

Novartis (cisplatin, cyclophosphamide) (confidentiality agreement not signed, not participating)

 

Pfizer (carboplatin, paclitaxel, cisplatin, doxorubicin, medroxyprogesterone acetate) (confidentiality agreement not signed, not participating)

 

Sandoz (cyclophosphamide) (confidentiality agreement not signed, not participating)

 

Seacross Pharmaceuticals (paclitaxel, doxorubicin) (confidentiality agreement not signed, not participating)

 

Teva UK (carboplatin, paclitaxel) (confidentiality agreement not signed, not participating)

General commentators

All Wales Therapeutics and Toxicology Centre

 

British National Formulary

 

Department of Health - Northern Ireland

 

Healthcare Improvement Scotland

 

Medicines and Healthcare products Regulatory Agency

 

Scottish Medicines Consortium

 

Welsh Government

Relevant research groups

Institute of Cancer Research

Timeline

Key events during the development of the guidance:

For further information on our processes and methods, please see our CHTE processes and methods manual